Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBiosyent Inc.

Biosyent Inc.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
17.15 CAD 0.30 ( 1.78%)
Last update at 2026-11-04T19:52:00Z
VOLUME
7099
Market Cap
170.43M
P/E
19.10

Momentum Score

…

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
16.85
Low
17.29
High
52 Week Price Range
10.08
Low
15.79
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Biosyent Inc. is a Canadian publicly listed life‑sciences company with limited public disclosures about its product portfolio and operations. Long-term growth may depend on regulatory approvals, licensing or commercial partnerships and successful market adoption of any proprietary or in‑licensed medicines. Investors may find potential upside if the company achieves clinical or commercial milestones and secures sustainable revenue streams.
Major risks include regulatory and clinical development uncertainty, likely limited scale and profitability, reliance on external financing, and execution risk in commercializing products.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
16.85
Dividend Yield
1.31%
Revenue TTM
43.05M
Revenue Per Share
3.82
Gross Profit TTM
32.96M
Debt / Equity
0.04
ROE
23.57%
Net Debt
-3.68M
ROCE
26.79%
Diluted EPS TTM
0.78

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 12.03M 9.78M 8.53M 7.43M 8.38M
Net income 9.01M 7.27M 6.46M 5.46M 6.28M
Selling general administrative 19.79M 17.65M 9.70M 8.86M 4.58M
Selling and marketing expenses - - 7.56M 6.42M 9.08M
Gross profit 32.96M 27.86M 25.14M 22.86M 22.64M
Reconciled depreciation 0.85M 0.59M 0.46M 0.45M 0.46M
Ebit - - 7.53M 7.43M 8.51M
Ebitda - - 7.99M 7.88M 8.97M
Depreciation and amortization - - 0.46M 0.45M 0.46M
Operating income 11.31M 9.06M 7.53M 6.98M 8.18M
Other operating expenses - - 24.06M 21.02M 20.37M
Interest expense 0.05M 0.06M 0.07M 0.08M 0.09M
Tax provision 3.02M 2.51M 2.07M 1.97M 2.10M
Interest income 0.81M 1.09M 1.13M 0.53M 0.14M
Net interest income 0.76M 1.03M 1.06M 0.45M 0.05M
Income tax expense - - 2.07M 1.97M 2.10M
Total revenue 43.05M 35.03M 31.59M 27.93M 28.62M
Total operating expenses 31.74M 25.97M 17.61M 15.95M 14.39M
Cost of revenue 10.09M 7.17M 6.45M 5.07M 5.98M
Total other income expense net -0.04M -0.31M 1.00M 0.45M 0.20M
Net income from continuing ops 9.01M 7.27M 6.46M 5.46M 6.28M
Net income applicable to common shares - - - 5.46M 6.28M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 49.44M 41.36M 41.53M 40.49M 37.17M
Intangible assets 4.80M 5.04M 1.15M 1.20M 0.87M
Other current assets - - 0.24M - -
Total liab 7.97M 6.36M 6.77M 7.12M 5.61M
Total stockholder equity 41.47M 35.00M 34.76M 33.36M 31.55M
Deferred long term liab - - - 0.17M 0.12M
Other current liab 0.02M - 0.14M 0.48M 0.41M
Common stock - - 5.12M 5.37M 5.80M
Capital stock 5.25M 5.31M 5.12M 5.37M 5.80M
Retained earnings 34.24M 27.73M 27.53M 25.91M 24.12M
Other liab - - - 0.18M 0.08M
Other assets - - 0.00M 0.64M 0.41M
Cash 21.79M 12.11M 4.91M 7.86M 18.04M
Total current liabilities 7.22M 5.41M 5.53M 5.72M 4.14M
Current deferred revenue - - 0.13M - -
Net debt - - -3.68M - -
Short term debt - - 0.18M - -
Short long term debt total - - 1.22M - -
Other stockholder equity - - 2.29M -0.14M -0.19M
Property plant equipment - - - 1.61M 1.85M
Total current assets 39.79M 24.47M 35.87M 37.14M 34.08M
Long term investments 3.29M 10.10M 2.50M - -
Net tangible assets - - - 32.27M 30.72M
Short term investments 6.86M 3.83M 21.28M 20.83M 10.18M
Net receivables 3.73M 2.39M 3.55M 3.66M 3.21M
Inventory 6.42M 5.33M 5.89M 4.54M 2.20M
Accounts payable 6.15M 4.00M 5.08M 5.06M 3.56M
Accumulated other comprehensive income - - -0.18M - -
Non currrent assets other - - -0.00M - -
Non current assets total 9.65M 16.89M 5.66M 3.34M 3.09M
Capital lease obligations 0.84M 1.04M 1.22M 1.40M 1.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 3.78M 6.77M 0.88M -10.65M -4.89M
Change to liabilities - - - 1.35M -0.78M
Total cashflows from investing activities - - - -10.79M -4.84M
Net borrowings -0.20M -0.18M - -0.16M -0.15M
Total cash from financing activities -3.41M -7.83M -5.78M -4.37M -2.08M
Change to operating activities - - - 0.20M -0.15M
Net income 9.01M 7.27M 6.46M 5.46M 6.28M
Change in cash 9.68M 4.13M -0.39M -10.17M -2.26M
Begin period cash flow 12.11M 7.98M 5.30M 18.04M 20.29M
End period cash flow 21.79M 12.11M 4.91M 7.86M 18.04M
Total cash from operating activities 9.01M 8.66M 5.83M 4.95M 4.67M
Depreciation 0.85M 0.59M 0.46M 0.45M 0.46M
Other cashflows from investing activities - - - 0.19M 0.15M
Dividends paid -2.25M 2.08M 1.91M 0.48M 0.01M
Change to inventory -1.24M 0.57M -1.48M -2.44M -0.13M
Change to account receivables - - 0.24M -0.43M -1.26M
Sale purchase of stock -0.21M -5.18M -3.70M -3.69M -1.85M
Other cashflows from financing activities - - -0.07M -0.08M -0.07M
Change to netincome - - - 0.13M 0.11M
Capital expenditures 0.39M 4.67M 2.67M 0.52M 0.09M
Change in working capital -0.91M 0.89M -1.45M -1.09M -2.18M
Stock based compensation 0.62M 0.55M 0.51M 0.44M 0.33M
Other non cash items -0.61M -1.04M -0.02M -0.30M -0.15M
Free cash flow 8.62M 3.99M 3.15M 4.43M 4.58M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RX
Biosyent Inc.		 0.30
1.78%		 17.15 19.10 15.85 3.96 4.11 3.31 11.03
DB
Decibel Cannabis Company Inc		 0.21
11.67%		 2.01 - 8.67 0.67 1.20 0.99 17.75
ZYUS
ZYUS Life Sciences Corporation		 0.03
9.38%		 0.35 - - 108.48 4.41 140.29 -4.26
LSL
LSL Pharma Group Inc.		 0.01
1.64%		 0.31 20.75 - 1.88 1.89 2.85 10.19
ROMJ
Rubicon Organics Inc		 0.04
10.67%		 0.41 28.50 38.02 0.65 0.87 0.79 9.17

Profile*

Biosyent Inc.

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.

2476 Argentia Road, Mississauga, ON, Canada, L5N 6M1

905-206-0013

https://www.biosyent.com

Name Title Year Born
Mr. René C. Goehrum Chairman, CEO & Pres 1959
Mr. Robert J. March VP of Fin. & CFO NA
Mr. Joost van der Mark VP of Corp. Devel. NA
Ms. Neelu Atwal Director of HR NA
Mr. Alfred D'Souza Advisor NA
Mr. René C. Goehrum Chairman, CEO & President 1959
Mr. Robert J. March VP of Finance & CFO NA
Mr. Joost van der Mark Vice President of Corporate Development NA
Ms. Neelu Atwal Director of Human Resources NA
Ms. Marnie Mccormick VP & GM NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…